Hansoh Pharmaceutical (03692): Xin Yue® (Inebilizumab Injection) Granted Third Indication by China's NMPA for Generalized Myasthenia Gravis

Intelligent Finance APP, HANSOH PHARMA (03692) announced that on March 25, 2026, the innovative drug Xinyue^®(Inebilizumab Injection) has been granted a drug registration certificate by the China National Medical Products Administration (NMPA), approving an additional indication: This product, in combination with conventional therapeutic agents, is used for the treatment of adult patients with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This is for Xinyue.^®The third approved indication.